Progenra Receives Approval of Novel Patent for Isopeptidase High Throughput Screening Platform
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Progenra, Inc., announced their receipt of an Official Notice of Allowance, dated June 15, 2010, of U.S. Patent Application No. 11/156,707, “Diagnostic and Screening Methods and Kits Associated with Proteolytic Activity.”
IP protection of this technology was also recently granted by the European Union. This technology is expected enable faster drug discovery by improving the ability to identify more selective drugs that modulate the handling of proteins associated with various disease states.
“This is a huge step forward, not only for Progenra, but for the industry,” said Michael Mattern, COO of Progenra. “This process condenses the timeline for drug discovery and in understanding drug efficacy and compatibility with the human body, while avoiding unnecessary expenditures associated with R&D.”
IP protection of this technology was also recently granted by the European Union. This technology is expected enable faster drug discovery by improving the ability to identify more selective drugs that modulate the handling of proteins associated with various disease states.
“This is a huge step forward, not only for Progenra, but for the industry,” said Michael Mattern, COO of Progenra. “This process condenses the timeline for drug discovery and in understanding drug efficacy and compatibility with the human body, while avoiding unnecessary expenditures associated with R&D.”
